Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
AstraZeneca
Johnson and Johnson
Mallinckrodt
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Volasertib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Volasertib: Sponsors, patents, clinical trial progress

Volasertib is an investigational drug.

There have been 25 clinical trials for Volasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Boehringer Ingelheim, National Comprehensive Cancer Network, and Yale University.

There are seventeen US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for Volasertib
TitleSponsorPhase
A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaUniversity of AlbertaPhase 1
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy FailedBoehringer IngelheimPhase 1
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCLBoehringer IngelheimPhase 1

See all Volasertib clinical trials

Clinical Trial Summary for Volasertib

Top disease conditions for Volasertib
Top clinical trial sponsors for Volasertib

See all Volasertib clinical trials

US Patents for Volasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Volasertib   Start Trial Specific salt, anhydrous and crystalline form of a dihydropteridione derivative Boehringer Ingelheim International GmbH (Ingelheim, DE)   Start Trial
Volasertib   Start Trial Process for the manufacture of dihydropteridinones Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Volasertib   Start Trial Intermediate compounds useful for the manufacture of dihydropteridinones Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Volasertib   Start Trial Process for the manufacture of dihydropteridinones Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Volasertib   Start Trial Specific salt, anhydrous and crystalline form of a dihydropteridione derivative Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Volasertib   Start Trial Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-et- hyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino- ]-3-methoxy-benzamide Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Volasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Volasertib Argentina 059349 2026-02-08   Start Trial
Volasertib Australia 2007213752 2026-02-08   Start Trial
Volasertib Brazil PI0707604 2026-02-08   Start Trial
Volasertib Canada 2635834 2026-02-08   Start Trial
Volasertib China 101379064 2026-02-08   Start Trial
Volasertib China 102093360 2026-02-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Johnson and Johnson
McKesson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.